---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-018908"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:06:00.603095+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Intensity Therapeutics posts Q2 2025 corporate presentation; no new material data disclosed

## Summary
- Presentation references lead candidate INT230-6 and DfuseRx platform for solid tumor treatment.
- No specific clinical results, financial updates, or guidance changes are included in the filed excerpt.
- Document furnished under Regulation FD; not deemed filed for SEC liability purposes.

## SEC filing metadata
- accession: 0001628280-25-018908
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000162828025018908/0001628280-25-018908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000162828025018908/intensity-20250422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-018908
- JSON: https://secwatch.observer/filing/0001628280-25-018908.json
- Plain text: https://secwatch.observer/filing/0001628280-25-018908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.